N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 / Phase 2 ClinicalTrials.gov

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier • ClinicalTrials.gov ID: NCT05786924

Registry updated: 2026-10-13
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC with KRAS and/or BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.

Interventions

  • S241656 (Drug)
    RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) and constitutively active CRAF, KRAS or NRAS mutations
  • FOLFOX6/FOLFOX7 (Drug)
    Used as a combination therapy and administered intravenously
  • FOLFIRI (Drug)
    Used as a combination therapy and administered intravenously
  • Cetuximab (Drug)
    Used as a combination therapy and administered intravenously
  • Panitumumab (Drug)
    Used as a combination therapy and administered intravenously
  • Gemcitabine (Drug)
    Used as a combination therapy and administered intravenously
  • Nab-paclitaxel (Drug)
    Used as a combination therapy and administered intravenously

Eligibility criteria

Key Inclusion Criteria: * Life expectancy of ≥ 12 weeks in the opinion of the investigator. * Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations or alterations. * Adequate bone marrow and organ function. * Recovered from toxicity to prior anti-cancer therapy. Part 1 Dose Escalation cohort ONLY: * Part 1A: Advanced/metastatic NSCLC with KRAS non-G12C, HRAS, NRAS, BRAF or CRAF (RAF1) mutations or alterations * Part 1B: Advanced/metastatic GI tumors (e.g., PDAC, CRC, and BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations * Part 1C: Advanced/metastatic PDAC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations * Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations * Part 1E: Other advanced/metastatic non-GI, non-NSCLC solid tumors with KRAS, HRAS, NRAS, BRAF, CRAF (RAF1) mutations or alterations Part 2 Dose Optimization and Expansion cohorts ONLY: * Part 2A: Advanced/metastatic NSCLC with KRAS non-G12C mutations and/or BRAF mutations * Part 2A1: Advanced/metastatic NSCLC with KRAS non-G12C mutations * Part 2A2: Advanced/metastatic NSCLC with BRAF mutations * Part 2A3: Advanced/metastatic NSCLC with KRAS non-G12C or BRAF mutations or alterations and active CNS metastatic disease * Part 2A4: Advanced/metastatic NSCLC with a KRAS G12C mutation * Part 2B1: Advanced/metastatic PDAC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations * Part 2B2: Advanced/metastatic CRC with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations * Part 2B3: Advanced/metastatic BTC (adenocarcinoma) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations Key Exclusion Criteria: * Cancer that has a known MEK1/2 mutation. * Known allergy/hypersensitivity to excipients of S241656 or to any of the registered IMPs administered in combination. * Any contra-indication, to use of any of the combination chemotherapy or anti-EGFR therapy partners administered as part of this trial. * Major surgery within 4 weeks of study entry or planned during study. * Ongoing anticancer therapy. * Ongoing radiation therapy. * Uncontrolled or active clinically relevant bacterial, fungal, or specific viral infection requiring systemic therapy. * Clinically significant cardiovascular disease. * Symptomatic spinal cord compression. * Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years. * History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO. * Females who are pregnant or breastfeeding. * Actively receiving systemic treatment or direct medical intervention on another therapeutic clinical study. * Prior use of experimental agents that target the KRAS/BRAF/MEK/ERK pathway.

Conditions

Non-small Cell Lung Cancer Histiocytic Neoplasm Histiocytosis BRAF Gene Mutation BRAF V600E BRAF V600 Mutation BRAF Mutation-Related Tumors BRAF Metastatic Lung Non-Small Cell Carcinoma Metastatic Lung Cancer Recurrent Lung Cancer Recurrent Lung Non-Small Cell Carcinoma NSCLC Solid Tumor Solid Carcinoma KRAS G12D KRAS G12V KRAS Mutation-Related Tumors NRAS Gene Mutation Thyroid Cancer Thyroid Carcinoma Colorectal Cancer Colorectal Carcinoma Recurrent Histiocytic and Dendritic Cell Neoplasm Brain Metastases Recurrent NSCLC KRAS G13C Acquired Resistance to KRAS G12C Inhibitor KRAS G12A KRAS G12F KRAS G12R KRAS G13D

Locations

  • Banner Health- MD Anderson Cancer Center — Gilbert, Arizona, United States
  • The Angeles clinic - A cedars SINAI AFFILIATE — Los Angeles, California, United States
  • USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
  • University of California, San Francisco (UCSF) — San Francisco, California, United States
  • University of Colorado - Aurora Cancer Center — Aurora, Colorado, United States
  • Yale University School of Medicine - Yale Cancer Center — New Haven, Connecticut, United States
  • Georgetown University Lombardi Cancer Center — Washington D.C., District of Columbia, United States
  • Sibley Memorial Hospital — Washington D.C., District of Columbia, United States
  • Dana-Farber Cancer Institute — Boston, Massachusetts, United States
  • South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan, United States
  • Masonic Cancer Center University of Minnesota — Minneapolis, Minnesota, United States
  • Washington University — St Louis, Missouri, United States
  • NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute) — New York, New York, United States
  • Memorial Sloan Kettering Cancer Center — New York, New York, United States
  • Duke University School of Medicine — Durham, North Carolina, United States
  • Cleveland Clinic — Cleveland, Ohio, United States
  • Sarah Canon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee, United States
  • MD Anderson Cancer Center — Houston, Texas, United States
  • START San Antonio — San Antonio, Texas, United States
  • NEXT Virginia — Fairfax, Virginia, United States
  • Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
  • Peter MacCallum Cancer Centre — East Melbourne, Australia
  • Westmead Hospital — Westmead, Australia
  • Beijing Cancer Hospital — Beijing, China
  • Shandong Cancer Hospital (Cancer Hospital of Shandong First Medical University) — Jinan, China
  • Fudan University Zhongshan Hospital — Shanghai, China
  • The Second Affiliated Hospital of Soochow University — Suzhou, China
  • Center for Cancer and Organ Diseases - Rigshospitalet — Copenhagen, Denmark
  • Centre Georges Francois Leclerc — Dijon, France
  • Institut Curie — Paris, France
  • AP-HP Hopital Europeen Georges Pompidou — Paris, France
  • Centre Eugene Marquis — Rennes, France
  • Institut Gustave Roussy — Villejuif, France
  • Queen Mary Hospital — Hong Kong, Hong Kong
  • Prince of Wales — Shatin, Hong Kong
  • Istituto Europeo di Oncologia — Milan, Italy
  • IFO - Istituto Nazionale dei Tumori Regina Elena — Rome, Italy
  • Istituto Clinico Humanitas — Rozzano, Italy
  • Kanagawa Cancer Center — Kanagawa, Japan
  • Kyoto University Hospital — Kyoto, Japan
  • National Cancer Center Hospital — Tokyo, Japan
  • Hospital Universitario Vall d'Hebron — Barcelona, Spain
  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz — Madrid, Spain
  • South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC — Madrid, Spain
  • Clinica Universidad de Navarra - Pamplona — Pamplona, Spain
  • Hospital Clinico Universitario de Valencia — Valencia, Spain
  • University College London Hospital — London, United Kingdom
  • Hammersmith Hospital — London, United Kingdom
  • The Christie NHS Foundation Trust — Manchester, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record